Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology
Anno:
2024
Background: Combinatorial therapy based on anthracyclines and HER-2 blocking agents increases the risk of cardiomyopathy in women with breast cancer. Fructose is a monosaccharide associated with high risk of diabetes, non-alcoholic fatty liver disease, atherosclerosis and visceral obesity. A high fructose diet is a potential cardiometabolic risk factor and…
Leggi di più
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity
Anno:
2024
Background: Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the development of cardiac dysfunction, arrhythmias, and clinical heart failure. Dapagliflozin exerts several…
Leggi di più
A RARE CASE OF IPILIMUMAB/NIVOLUMAB-INDUCED MYOCARDITIS COMPLICATED BY HIGH GRADE ATRIOVENTRICULAR BLOCK IN A PATIENT WITH METASTATIC RENAL CELL CANCER
Anno:
2024
Background Immune checkpoint inhibitors (ICIs) such as Ipilimumab and Nivolumab have revolutionized the field of cancer therapy. These monoclonal antibodies help to reinforce antitumor immunity, resulting in robust activation of the immune system which promotes tumor cell death. T-cell-targeted immunomodulators are now widely used in the treatment of about…
Leggi di più
Combinatorial immune checkpoint blockade increases myocardial secretion of H-FABP, NT-Pro-BNP, NLRP-3 inflammasome, Interleukin-1β and Interleukin-6: biochemical implications in cardio-immuno-oncology
Anno:
2024
Background: Immune checkpoint blockade have become an integral part of oncology in recent years. Monoclonal antibodies against CTLA-4 or PD-1 or PDL-1 are the most studied ICIs in randomized clinical trials, however, more recently, an anti-LAG3 monoclonal antibody, Relatlimab, has been approved by FDA for combinatorial treatment with Nivolumab…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram